Compare Direxion Daily Semiconductor Bull 3X Shares (SOXL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bull 3X Shares vs Vertex Pharmaceuticals Incorporated — how do they compare? Direxion Daily Semiconductor Bull 3X Shares trades at $138.12 (market cap $24.42B), while Vertex Pharmaceuticals Incorporated trades at $509.61 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.2× Direxion Daily Semiconductor Bull 3X Shares's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily Semiconductor Bull 3X Shares for 15 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SOXL | VRTX | |
|---|---|---|
Market Cap | $24.42B | $127.55B |
Volume | 100,232,380 | 1,487,944 |
Sector | Leveraged / Inverse | Health |
52-Week High | $300.77 | $557.96 |
52-Week Low | $30.81 | $407.37 |
Typical Hold Time | 15 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXL, the Direxion Daily Semiconductor Bull 3X ETF, trades at $141.3, down 11.08% with a bearish technical signal despite bullish moving averages. The semiconductor sector shows volatility with mixed news flow, ranging from strong AI demand to regulatory and tariff concerns. Recent price action reflects the leveraged ETF's sensitivity to chip stock movements, with support at $134 and resistance at $145.
Outlook remains cautious due to high leverage amplifying sector swings. Opportunities exist if semiconductor fundamentals strengthen, but risks include overcrowded trades and macroeconomic headwinds. Investors should weigh the ETF's structure against direct semiconductor exposure for risk management.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
